Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533387 · ClinicalTrials.gov registry record · Phase 1
Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers
A Phase 1 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03533387 is a Phase 1 study that has completed, run by MediciNova. The registered enrollment target is 28 participants.
The verdict
NCT03533387, a Phase 1 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers
Interventions
- DRUG MN-166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533387
The ClinicalTrials.gov registry entry for NCT03533387 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MN-166 is the first listed.
NCT03533387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03533387 about?
NCT03533387 is a clinical study titled "Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers". To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers
What is the current status of trial NCT03533387?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-04-11. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT03533387?
The interventions under investigation include: MN-166 (DRUG).
Who is sponsoring clinical trial NCT03533387?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.